Daniel W. Muehl
Net Worth

Last updated:

What is Daniel W. Muehl net worth?

The estimated net worth of Mr. Daniel W. Muehl is at least $6,127,292 as of 2 Sep 2022. He owns shares worth $8,052 as insider, has earned $359,400 from insider trading and has received compensation worth at least $5,759,840 in Clovis Oncology, Inc..

What is the salary of Daniel W. Muehl?

Mr. Daniel W. Muehl salary is $719,980 per year as Executive Vice President & Chief Financial Officer in Clovis Oncology, Inc..

How old is Daniel W. Muehl?

Mr. Daniel W. Muehl is 61 years old, born in 1964.

What stocks does Daniel W. Muehl currently own?

As insider, Mr. Daniel W. Muehl owns shares in one company:

Company Title Shares Price per share Total value
Clovis Oncology, Inc. (CLVS) Executive Vice President & Chief Financial Officer 99,161 $0.08 $8,052

What does Clovis Oncology, Inc. do?

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

CLVS logo
CLVS
Clovis Oncology, Inc.
$0.08

Daniel W. Muehl insider trading

Clovis Oncology, Inc.

Mr. Daniel W. Muehl has made 41 insider trades between 2017-2022, according to the Form 4 filled with the SEC. Most recently he sold 2,234 units of CLVS stock worth $2,681 on 2 Sep 2022.

The largest trade he's ever made was exercising 24,125 units of CLVS stock on 1 Feb 2021. As of 2 Sep 2022 he still owns at least 99,161 units of CLVS stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 2,234 $1.2 $2,681
Option
Common Stock 5,063 N/A N/A
Option
Restricted Stock Units 5,063 N/A N/A
Option
Restricted Stock Units 4,625 N/A N/A
Sale
Common Stock 2,554 $1.46 $3,731
Sale
Common Stock 2,100 $1.46 $3,068
Option
Restricted Stock Units 5,624 N/A N/A
Option
Common Stock 4,625 N/A N/A
Option
Common Stock 5,624 N/A N/A
Sale
Common Stock 2,327 $0.64 $1,494
Option
Restricted Stock Units 5,062 N/A N/A
Option
Common Stock 5,062 N/A N/A
Option
Restricted Stock Units 4,625 N/A N/A
Sale
Common Stock 2,062 $1.97 $4,062
Sale
Common Stock 2,508 $1.97 $4,941
Option
Restricted Stock Units 5,623 N/A N/A
Option
Common Stock 5,623 N/A N/A
Option
Common Stock 4,625 N/A N/A
Option
Restricted Stock Units 563 N/A N/A
Sale
Common Stock 10,416 $1.87 $19,436
Sale
Common Stock 290 $1.87 $541
Option
Restricted Stock Units 20,250 N/A N/A
Option
Common Stock 563 N/A N/A
Option
Common Stock 20,250 N/A N/A
Sale
Common Stock 2,453 $1.94 $4,759
Sale
Common Stock 2,983 $1.94 $5,787
Option
Restricted Stock Units 5,625 N/A N/A
Option
Restricted Stock Units 4,625 N/A N/A
Option
Common Stock 10,250 N/A N/A
Sale
Common Stock 248 $3 $744
Option
Restricted Stock Units 562 N/A N/A
Option
Common Stock 562 N/A N/A
Sale
Common Stock 4,523 $4.55 $20,580
Option
Restricted Stock Units 10,248 N/A N/A
Option
Common Stock 10,248 N/A N/A
Sale
Common Stock 249 $4.89 $1,218
Option
Common Stock 563 N/A N/A
Option
Restricted Stock Units 563 N/A N/A
Sale
Common Stock 4,507 $4.82 $21,724
Option
Common Stock 10,249 N/A N/A
Option
Restricted Stock Units 10,249 N/A N/A
Sale
Common Stock 231 N/A N/A
Option
Restricted Stock Units 562 N/A N/A
Option
Common Stock 562 N/A N/A
Sale
Common Stock 4,837 N/A N/A
Sale
Common Stock 4,837 $5.54 $26,797
Option
Restricted Stock Units 10,248 N/A N/A
Option
Common Stock 10,248 N/A N/A
Option
Common Stock 1,032 N/A N/A
Option
Common Stock 1,032 N/A N/A
Sale
Common Stock 456 $6.29 $2,868
Option
Restricted Stock Units 1,032 N/A N/A
Sale
Common Stock 456 N/A N/A
Option
Restricted Stock Units 1,032 N/A N/A
Sale
Common Stock 11,872 N/A N/A
Option
Restricted Stock Units 24,125 N/A N/A
Option
Restricted Stock Units 24,125 N/A N/A
Option
Common Stock 24,125 N/A N/A
Option
Restricted Stock Units 1,031 N/A N/A
Sale
Common Stock 457 $4.89 $2,235
Option
Common Stock 1,031 N/A N/A
Option
Restricted Stock Units 5,623 N/A N/A
Sale
Common Stock 2,534 $4.93 $12,493
Sale
Common Stock 2,534 $4.93 $12,493
Option
Common Stock 5,623 N/A N/A
Option
Common Stock 1,032 N/A N/A
Sale
Common Stock 435 $5.3 $2,306
Option
Restricted Stock Units 1,032 N/A N/A
Sale
Common Stock 242 $5.07 $1,227
Option
Common Stock 547 N/A N/A
Option
Restricted Stock Units 547 N/A N/A
Sale
Common Stock 2,506 $5.92 $14,836
Option
Restricted Stock Units 5,624 N/A N/A
Option
Common Stock 5,624 N/A N/A
Option
Restricted Stock Units 1,030 N/A N/A
Sale
Common Stock 470 $7.03 $3,304
Option
Common Stock 1,030 N/A N/A
Sale
Common Stock 247 $6.91 $1,707
Option
Common Stock 547 N/A N/A
Option
Restricted Stock Units 547 N/A N/A
Sale
Common Stock 2,213 $8.1 $17,925
Option
Common Stock 5,623 N/A N/A
Option
Restricted Stock Units 5,623 N/A N/A
Sale
Common Stock 475 $7.2 $3,420
Option
Restricted Stock Units 1,032 N/A N/A
Option
Common Stock 1,032 N/A N/A
Option
Common Stock 547 N/A N/A
Option
Restricted Stock Units 547 N/A N/A
Sale
Common Stock 279 $6.9 $1,925
Option
Restricted Stock Units 22,497 N/A N/A
Option
Common Stock 22,497 N/A N/A
Sale
Common Stock 10,472 $8.41 $88,070
Sale
Common Stock 466 $14.59 $6,799
Option
Common Stock 1,031 N/A N/A
Option
Restricted Stock Units 1,031 N/A N/A
Option
Common Stock 546 N/A N/A
Sale
Common Stock 242 $10.2 $2,468
Option
Restricted Stock Units 546 N/A N/A
Sale
Common Stock 495 $5.21 $2,579
Option
Common Stock 1,032 N/A N/A
Option
Restricted Stock Units 1,032 N/A N/A
Sale
Common Stock 239 $6.09 $1,456
Option
Restricted Stock Units 547 N/A N/A
Option
Common Stock 547 N/A N/A
Option
Common Stock 1,030 N/A N/A
Option
Restricted Stock Units 1,030 N/A N/A
Sale
Common Stock 453 $15.07 $6,827
Sale
Common Stock 271 $14.88 $4,032
Option
Common Stock 547 N/A N/A
Option
Restricted Stock Units 547 N/A N/A
Option
Restricted Stock Units 2,719 N/A N/A
Sale
Common Stock 1,297 $29.29 $37,989
Option
Restricted Stock Units 469 N/A N/A
Option
Common Stock 469 N/A N/A
Option
Common Stock 2,719 N/A N/A
Option
Common Stock 547 N/A N/A
Sale
Common Stock 266 $25.9 $6,889
Option
Restricted Stock Units 547 N/A N/A
Sale
Common Stock 188 $21.23 $3,991
Option
Restricted Stock Units 469 N/A N/A
Option
Common Stock 469 N/A N/A
Option
Common Stock 546 N/A N/A
Option
Restricted Stock Units 546 N/A N/A
Option
Common Stock 469 N/A N/A
Option
Restricted Stock Units 469 N/A N/A
Option
Restricted Stock Units 547 N/A N/A
Option
Common Stock 547 N/A N/A
Option
Restricted Stock Units 468 N/A N/A
Option
Common Stock 468 N/A N/A
Option
Restricted Stock Units 547 N/A N/A
Option
Common Stock 547 N/A N/A
Option
Common Stock 1,875 N/A N/A
Option
Restricted Stock Units 1,875 N/A N/A
Option
Restricted Stock Units 547 N/A N/A
Option
Common Stock 547 N/A N/A
Option
Restricted Stock Units 547 N/A N/A
Option
Common Stock 547 N/A N/A
Option
Restricted Stock Units 2,188 N/A N/A
Option
Common Stock 2,188 N/A N/A
Option
Common Stock 1,250 N/A N/A

Clovis Oncology key executives

Clovis Oncology, Inc. executives and other stock owners filed with the SEC:

  • Dr. Gillian C. Ivers-Read (71) Co-Founder, Chief Regulatory Officer & Executive Vice President of Technical Operations
  • Dr. Lindsey Rolfe B.Sc., BSc, MB ChB, MRCP, FFPM (57) Executive Vice President of Clinical Devel. & Pharmacovigilance and Chief Medical Officer
  • Mr. Daniel W. Muehl (61) Executive Vice President & Chief Financial Officer
  • Mr. Patrick J. Mahaffy (62) Co-Founder, Chief Executive Officer, Pres & Executive Director
  • Mr. Paul Edward Gross (60) Executive Vice President, Gen. Counsel & Sec.